Tower Research Capital (TRC)’s RAPT Therapeutics RAPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-3,085
| Closed | -$104K | – | 5485 |
|
|
2025
Q4 | $104K | Buy |
+3,085
| New | +$95.8K | ﹤0.01% | 1914 |
|
|
2025
Q3 | – | Sell |
-1,918
| Closed | -$15.3K | – | 5553 |
|
|
2025
Q2 | $15.3K | Buy |
1,918
+171
| +10% | +$1.3K | ﹤0.01% | 3815 |
|
|
2025
Q1 | $17K | Buy |
1,747
+295
| +20% | +$2.9K | ﹤0.01% | 3129 |
|
|
2024
Q4 | $18.4K | Buy |
1,452
+791
| +120% | +$10K | ﹤0.01% | 3258 |
|
|
2024
Q3 | $10.6K | Sell |
661
-684
| -51% | -$13.8K | ﹤0.01% | 3736 |
|
|
2024
Q2 | $32.8K | Buy |
1,345
+841
| +167% | +$38.8K | ﹤0.01% | 3417 |
|
|
2024
Q1 | $36.2K | Sell |
504
-756
| -60% | -$105K | ﹤0.01% | 2494 |
|
|
2023
Q4 | $251K | Buy |
1,260
+1,164
| +1,213% | +$144K | ﹤0.01% | 1909 |
|
|
2023
Q3 | $12.7K | Sell |
96
-278
| -74% | -$45.4K | ﹤0.01% | 3873 |
|
|
2023
Q2 | $56K | Buy |
374
+119
| +47% | +$18.5K | ﹤0.01% | 2495 |
|
|
2023
Q1 | $37K | Sell |
255
-486
| -66% | -$98.3K | ﹤0.01% | 2789 |
|
|
2022
Q4 | $118K | Sell |
741
-131
| -15% | -$21K | ﹤0.01% | 1705 |
|
|
2022
Q3 | $168K | Buy |
872
+711
| +442% | +$134K | ﹤0.01% | 2092 |
|
|
2022
Q2 | $23K | Sell |
161
-48
| -23% | -$6.4K | ﹤0.01% | 3661 |
|
|
2022
Q1 | $37K | Sell |
209
-208
| -50% | -$39.3K | ﹤0.01% | 2966 |
|
|
2021
Q4 | $123K | Buy |
417
+255
| +157% | +$68.2K | ﹤0.01% | 2092 |
|
|
2021
Q3 | $40K | Buy |
162
+24
| +17% | +$6.34K | ﹤0.01% | 3130 |
|
|
2021
Q2 | $35K | Sell |
138
-58
| -30% | -$10.8K | ﹤0.01% | 3331 |
|
|
2021
Q1 | $35K | Sell |
196
-129
| -40% | -$21.3K | ﹤0.01% | 3431 |
|
|
2020
Q4 | $51K | Sell |
325
-869
| -73% | -$189K | ﹤0.01% | 3106 |
|
|
2020
Q3 | $308K | Buy |
1,194
+1,073
| +887% | +$238K | ﹤0.01% | 2160 |
|
|
2020
Q2 | $28K | Buy |
+121
| New | +$18.7K | ﹤0.01% | 3490 |
|
|
2020
Q1 | – | Sell |
-117
| Closed | -$26K | – | 3741 |
|
|
2019
Q4 | $26K | Buy |
+117
| New | +$21.5K | ﹤0.01% | 1761 |
|
Tower Research Capital (TRC)'s RAPT Position: Q1 2026 in Review
Tower Research Capital (TRC) sold out of RAPT Therapeutics (RAPT) in Q1 2026, closing a stake of 3,085 shares — an estimated $104K sold.
Tower Research Capital (TRC) first reported a position in RAPT in Q4 2019 and held it in 23 quarters. The position peaked at $308K in Q3 2020. 0 funds tracked by Wall St. Rank hold RAPT as of Q1 2026.
- Tower Research Capital (TRC) reported no remaining RAPT Therapeutics position as of Q1 2026 after selling out during the quarter.
- Tower Research Capital (TRC) sold 3,085 RAPT Therapeutics shares in Q1 2026, an estimated $104K.
- Tower Research Capital (TRC) first reported a position in RAPT Therapeutics in Q4 2019 and held it in 23 quarters.
- Tower Research Capital (TRC)'s RAPT Therapeutics position peaked at $308K in Q3 2020.
- 0 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.